Antonio Piga

TL;DR: Survival and complication-free survival of patients with thalassemia major continue to improve, especially for female patients born shortly before or after the availability of iron chelation.

TL;DR: A comparative phase 3 trial was conducted to demonstrate the efficacy of deferasirox in regularly transfused patients with beta-thalassemia aged 2 years or older, and found it to be a promising once-daily oral therapy for the treatment of transfusional iron overload.

TL;DR: Overall survival from birth for patients born in 1970-74 was 97.4% at 10 years, and 94.8% at 15 years, while the most common cause of death was heart disease, followed by infection, liver disease, and malignancy.

TL;DR: Deferiprone monotherapy was significantly more effective than deferoxamine over 1 year in improving asymptomatic myocardial siderosis in beta-thalassemia major.

TL;DR: Insulin resistance is a major, independent risk factor for advanced fibrosis in patients with NAFLD, and increased ferritin levels are markers of severe histologic damage, but not of iron overload.